KRAS and neoplasm: Ruess et al. found that PTPN11 gene deletion significantly inhibited tumor development in KRAS-driven pancreatic ductal adenocarcinoma and non-small cell lung cancer mouse models, providing evidence for the critical dependence of mutant KRAS on SHP2 in the process of carcinogenesis [43].